AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00729404
Drug: Ethinylestradiol/Gestodene (BAY86-5016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: transdermal patch: 0.55mg EE+1.05 mg GSD; 3x7 days patch- wearing phase and a patch-free interval of 7 days (1 pre-treatment cycle, 3 treatment cycles
Trial: NCT00427440
Drug: AMG 102 at 20 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 102 at 20 mg/kg IV (in the vein) every 2 weeks
Trial: NCT01846182
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02181985
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03923933
Drug: Chlorthalidone
RxNorm normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone
Trial: NCT03923933
Drug: Bumetanide
RxNorm normalized name: Bumetanide
DrugBank: Bumetanide (DB00887)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bumetanide
Trial: NCT00460837
Drug: bowel preparation: senna & gastrofin versus picolax (standard)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention is a bowel cleansing procedure
Trial: NCT02275065
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match bictegravir administered orally once daily
Trial: NCT00377403
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptomatic treatment:~Dose: 500mg every 4 to 6 hours for pain or fever
Trial: NCT03451734
Drug: antipsychotic medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: olanzapine, risperidone, aripiprazole, amisulpride, ziprasidone, and haloperidol groups
Trial: NCT03451734
Drug: adjunctive group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: antipsychotic plus placebo, antipsychotic plus sulforaphane(3 tables per day, consisting of 30 mg of SFN-glucosinolate per day), and antipsychotic plus minocycline(200mg per day) groups.
Trial: NCT01538732
Drug: alitretinoin
RxNorm normalized name: Alitretinoin
DrugBank: Alitretinoin (DB00523)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30mg capsules (Alitretinoin)will be taken peroral once daily with a meal. Study treatment will be given for a total duration of up to 24 weeks
Trial: NCT01278134
Drug: Copegus placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg or 1200 mg daily orally in split doses (morning/evening), up to 24 weeks
Trial: NCT01278134
Drug: RO5024048
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg bid orally, up to 24 weeks
Trial: NCT00719862
Drug: Placebo nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00003038
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02982005
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered placebo by subcutaneous (SC) injection until week 12. Administered KHK4827 by SC injection from week 13 until week 62.
Trial: NCT02657031
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline 500 cc IV Bolus
Trial: NCT01652144
Drug: AT7519M
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00427440
Drug: AMG 102 at 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 102 at 10 mg/kg IV (in the vein) every 2 weeks
Trial: NCT01511510
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral solution Q24 hours for 14 days
Trial: NCT01938612
Drug: MEDI4736
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI4736 will be administered by IV infusion every 14, 21 or 28 days.
Trial: NCT01750073
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01750073
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00115115
Drug: Dopamine infusion to brain dead organ donors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine infusion administered at a dosage of 4µg/kg/min starting after brain death has been proven until to surgical procurement of the kidneys
Trial: NCT01563536
Drug: ABT-267
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT01563536
Drug: ABT-450
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT01563536
Drug: ABT-333
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT01844752
Drug: NVN1000 1% Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily NVN1000 1% Gel for 12 weeks
Trial: NCT01844752
Drug: NVN1000 4% Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily NVN1000 4% Gel for 12 weeks
Trial: NCT01844752
Drug: Vehicle Gel
RxNorm normalized name: vehicle gel base no.61
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily Vehicle Gel for 12 weeks
Trial: NCT00567190
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (matching pertuzumab) was administered intravenously.
Trial: NCT02226913
Drug: 2% lidocaine with 1:80,000 epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lidocaine with 1:80,000 epinephrine
Trial: NCT02226913
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sterile distilled water (Samen Pharmaceutical Co, Iran)
Trial: NCT02332590
Drug: Placebo (for sarilumab)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: solution for injection in pre-filled syringe; Route of administration: SC
Trial: NCT02332590
Drug: Placebo (for adalimumab)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: solution for injection in pre-filled syringe; Route of administration: SC
Trial: NCT00826826
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: From the day of the catheter ablation procedure and 8 weeks forward.
Trial: NCT00211705
Drug: Diet+pravastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04598867
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules
Trial: NCT04598867
Drug: Afobazol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afobazol 10 mg tabletes
Trial: NCT02669784
Drug: Low Dose Contrast (Omnipaque) 40mL
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patient will be administered a low dose, 40mL of intravenous contrast (Omnipaque) at a rate of 5mL/sec based on the area of the body being scanned (chest versus chest and abdomen versus chest, abdomen and pelvis). This will be compared to the patient's prior examination performed with 100mL of intravenous contrast at a rate of 4mL/sec.
Trial: NCT02669784
Drug: Low Dose Contrast (Omnipaque) 50 mL
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patient will be administered a low dose, 50mL of intravenous contrast (Omnipaque) at a rate of 5mL/sec based on the area of the body being scanned (chest versus chest and abdomen versus chest, abdomen and pelvis). This will be compared to the patient's prior examination performed with 100mL of intravenous contrast at a rate of 4mL/sec.
Trial: NCT02571517
Drug: Glucocorticoids
RxNorm normalized name: GLUCOCORTICOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients assigned to experimental group (group 1) will receive iv methylprednisolone 2 mg/kg/day (divided in two doses) doses and/or oral prednisolone 2,5 mg/kg/day (divided in two doses) during 7 days.
Trial: NCT01489943
Drug: Rosuvastatin 10 mg
RxNorm normalized name: rosuvastatin 10 MG
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects will receive 10 mg tablet of Rosuvastatin orally once daily on Days 4 and 14. Rosuvastatin will be administered with 240 mL of water.
Trial: NCT02953301
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02136940
Drug: AMA0076
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02136940
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01024608
Drug: Placebo Nasal Aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo nasal aerosol administered each morning for two weeks.
Trial: NCT03253224
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline group receives the same volume of normal saline, administered according to the same method as in the magnesium group.
Trial: NCT03846648
Drug: Cypep-1
RxNorm normalized name: Cypex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible subjects will be randomized to one of the two treatment groups in a ratio of 1:1 (active:placebo).~The treatment groups are:~* CyPep-1 topical formulation 1% (w/w)~* Vehicle topical formulation (placebo) The minimum set of studied warts is 1 treated common wart per subject. The subjects will be randomly assigned to treatment. During the treatment period topical formulation will be applied daily on to a maximum of 3 warts. One selected wart will serve as target wart, i.e. the primary wart, for detailed analysis. Selection of warts will be based on the feasibility to conduct treatment application and pharmacodynamics (including biopsy sampling) on the region of interest.
Trial: NCT03538951
Drug: 20% VDA-1102
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg once-daily for 12 weeks
Trial: NCT03174613
Drug: LC51-0255
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25mg, 0.5mg, 1mg, 2mg, 4mg, 8mg
Trial: NCT02697851
Drug: Microgynon 30®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02697851
Drug: Evotaz®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00254202
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03174613
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25mg, 0.5mg, 1mg, 2mg, 4mg, 8mg
Trial: NCT01091051
Drug: Placebo (Soduim Chloride)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized to placebo (10 with PPPP and 10 with PPP) will receive placebo at Weeks 0 and 4 and ustekinumab at Weeks 16 and 20
Trial: NCT03920228
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo topical
Trial: NCT00005092
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV over 2 hours on days 2 and 3
Trial: NCT00206401
Drug: Lantus and short acting analogs Vs NPH and short acting analogs
RxNorm normalized name: Short-acting sulfonamides
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02233907
Drug: Ventilat® - metered dose inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02894528
Drug: BioMend without ReproBone
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Post-extraction the socket was filled only by clot and covered by a resorbable collagen membrane BioMend, which in turn was covered by a flap.
Trial: NCT01990846
Drug: Flufirvitide 3
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01990846
Drug: Placebo for Flufirvitide-3
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03625401
Drug: AD-35 60mg group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AD-35 60mg QD
Trial: NCT03625401
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: 3 placebo of AD-35 30mg tablets
Trial: NCT02119260
Drug: Placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clear, colourless solution of aqueous citrate buffer with 4% captisol
Trial: NCT02119260
Drug: Placebo suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Visually matching aqueous suspension of hypromellose acetate succinate powder
Trial: NCT02119260
Drug: Placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching white opaque placebo blend filled capsule
Trial: NCT00800839
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dose of 50 mg/kg by vein over 3 hours on Days 3 and 4.
Trial: NCT00265980
Drug: Subcutaneous Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily injections of saline in the same volume as will be used for leptin injections.
Trial: NCT01452633
Drug: 0.25% bupivicaine will be injected at the study port site prior to incision
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection will precede the incision
Trial: NCT01452633
Drug: Saline will be in injected into the port site prior to closure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline will be injected into the port site prior to the closure without any preincisional intervention
Trial: NCT01452633
Drug: 0.25% bupivicaine will be injected into the port site prior to closure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25% bupivicaine will be injected into the port site at closure without any preincisional intervention
Trial: NCT00967226
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.0 mg/kg orally, 2 per day 4-6 months
Trial: NCT02586025
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo by IV infusion in 3-week cycles as neoadjuvant treatment (Cycles 1-4)and as adjuvant treatment (Cycles 8-20)
Trial: NCT02562872
Drug: DSM265
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DSM265 400 mg single oral dose
Trial: NCT00155389
Drug: Helicobacter pylori eradication
RxNorm normalized name: Helicobacter pylori
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For subjects who received the first-line treatment, the costs included the initial 13C-UBT, one-week triple therapy (esomeprazole 40mg once daily, amoxicillin 1g twice daily, and clarithromycin 500mg twice daily), and the confirmatory 13C-UBT. For subjects in whom the initial treatment failed, the costs further included the re-treatment consisting of ten-day triple therapy (esomeprazole 40mg once daily, amoxicillin 1g twice daily, and levofloxacin 500mg once daily), and the confirmatory 13C-UBT.~The first round of study was between 2004 and 2005, the second round was between 2008 and 2009, and the third round was between 2012 and 2013.
Trial: NCT02562872
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match DSM265, single oral dose
Trial: NCT01183663
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg/m2 by vein on day 1 of a 21 day cycle.
Trial: NCT00003617
Drug: clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02120027
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet (identical in appearance and weight to ibodutant tablets) to be given once daily.
Trial: NCT02701985
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching-placebo capsules will be administered orally, 2 times a day with food.
Trial: NCT01002872
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial dose of placebo will be 1 pill three times a day
Trial: NCT03432923
Drug: Benzocaine 8 mg
RxNorm normalized name: benzocaine 8 MG
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benzocaine 8 mg, oval, white to slightly beige to yellow film coated tablet. One lozenge to be dissolved slowly in the mouth every 2 hours. Max 6 per day, max treatment 5 days.
Trial: NCT01259050
Drug: Zinc and Copper
RxNorm normalized name: copper gluconate / zinc picolinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optizinc 90 mg/d Copper 1 mg
Trial: NCT00640627
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg oral capsule once daily for 6 weeks
Trial: NCT00640627
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched oral placebo for 6 weeks
Trial: NCT02332720
Drug: MK-3682B
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part B and Part C: two FDC tablets, each containing grazoprevir 50 mg + elbasvir 225 mg + ruzasvir 30 mg, taken q.d. by mouth.
Trial: NCT04517864
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet, dosed as 4 tablets QD or 1 tablet QD
Trial: NCT00444470
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible patients who have consented to be in the study and have been randomised to be in Arm B will receive 10 mg/kg of placebo followed by a continuous infusion of 1 mg/kg/hr of placebo.
Trial: NCT03233243
Drug: Rosuvastatin Oral Tablet
RxNorm normalized name: rosuvastatin Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with 18F-NaF-positive plaques will be treated with 20 mg of rosuvastatin daily for six months, except in patients who need a 55% LDL reduction to achieve recommended targets (rosuvastatin 40 mg). A second visit (visit 2) will take place eight weeks after therapy initiation to monitor for compliance and adverse events report: therapy will be discontinued if there is an elevation of creatine kinase over five times the ULN with myalgia or alanine amino-transferase three times the ULN.
Trial: NCT01315093
Drug: Heparin, Low-Molecular-Weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin from start till hcg test
Trial: NCT01315093
Drug: no heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04487093
Drug: neoantigen vaccine + anti-angioge
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: neoantigen vaccine + anti-angioge
Trial: NCT03105674
Drug: Multi-drug local anesthetics (Combination)
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Ropivacaine 0.5% - 30 ml~2. Ketorolac 30mg/ml - 1 ml~3. Kenalog 10 mg/ml - 5 ml~4. Lidocaine 1% with Epinephrine 1:100,000 - 20ml
Trial: NCT03105674
Drug: Standard local anesthetics (Combination)
RxNorm normalized name: local opthalmologic anesthetic combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marcaine and Lidocaine
Trial: NCT01034267
Drug: F2695 SR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug F2695 SR (flexible dose) to be given orally in capsule form once daily
Trial: NCT02975570
Drug: WHO MDR-TB regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The WHO guidelines recommend the following 5-agent treatment regimen for MDR-TB: pyrazinamide; a fluoroquinolone; a parenteral agent (typically amikacin or kanamycin); ethionamide (or prothionamide); and either cycloserine or para-aminosalicylic acid, with preference for cycloserine. Short (9 mos) or longer (20-24 mos) treatment schedules can be used.
Trial: NCT03255824
Drug: Propofol, Midazolam, and Fentanyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of Propofol, Midazolam, and Fentanyl for sedation during third molar surgery.
Trial: NCT00677833
Drug: Azithromycin plus Chloroquine
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combination of Azithromycin plus Chloroquine Azithromycin (\~30 mg/kg) + chloroquine (\~10mg base /kg) combination tablet(s) on weight basis, once daily for 3 days (Days 0,1,2) or Artemether-lumefantrine tablet(s) based on weight and labeling for 3 days (Days 0, 1, 2)
Trial: NCT04424862
Drug: Ponticelli Regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Month 1: i.v. methylprednisolone (0.5 g) daily for three doses, then oral prednison (0.5 mg/kg/d, maximum dose 30mg/d) for 27 days Month 2: Oral cyclophosphamide (2.0 mg/kg/d, maximum dose 100mg/d) for 30 days Month 3: Repeat Month 1 Month 4: Repeat Month 2 Month 5: Repeat Month 1 Month 6: Repeat Month 2
Trial: NCT02037048
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02037048
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00678314
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml
Trial: NCT01698684
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One dose 15 minutes before attempting intercourse
Trial: NCT02184611
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blended with lactose and magnesium stearate dry white powder to be inhaled via a NDPI
Trial: NCT04493216
Drug: GSK3640254
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3640254 was available as a 25 mg and 100 mg tablets to be administered via oral route.
Trial: NCT04493216
Drug: FTC/TAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FTC/TAF was available as emtricitabine 200 mg/tenofovir alafenamide 25 mg tablet to be administered via oral route.
Trial: NCT04493216
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching GSK3640254 was administered in the form of tablets via oral route.
Trial: NCT04700436
Drug: Rosuzet tablet 10/5 mg (Ezetimibe 10 mg/Rosuvastatin 5 mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IP~* Test drug: Rosuzet tablet 10/5 mg (Ezetimibe 10 mg/Rosuvastatin 5 mg)~* Control drug: Suvast tablet 10 mg (Rosuvastatin 10 mg)